|
|
| (103 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | {{tp|p=32311318|t=ä. SARS-CoV-2 and ''viral sepsis'': observations and hypotheses |pdf=|usr=}}
| |
| − | {{tp|p=32325026|t=2020. Endothelial cell infection and endotheliitis in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − |
| |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32360205|t=ä. What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32336069|t=2020. What should a cardiologist know about coronavirus disease 2019?|pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Structure of covid19]]''' | + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32350227|t=2020. Characteristics of SARS-CoV-2 isolated from asymptomatic carrier in Tokyo |pdf=|usr=}}
| + | |
| − | {{tp|p=32007145|t=2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 34: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32213336|t=ä. SARS-CoV-2: virus dynamics and host response |pdf=|usr=}}
| |
| − | {{tp|p=32213337|t=ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study |pdf=|usr=}}
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | + | *'''[[Pathobiology]]''' |
| | | | |
| | | | |
| − | *'''[[Early symptoms]]''' | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[Systemic disease, any manifestations]]'''
| |
| | | | |
| − | *'''[[Co-Infection]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32307254|t=ä. Invasive fungal diseases during COVID-19: We should be prepared |pdf=|usr=}}
| + | |
| − | {{tp|p=32297939|t=ä. SARS-CoV-2 and Legionella Co-infection in a Person Returning from a Nile Cruise |pdf=|usr=}}
| + | |
| − | {{tp|p=32293646|t=ä. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]'''
| |
| − | {{tp|p=32330428|t=ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Early symptoms]]''' |
| | | | |
| | + | *'''[[Systemic disease, any manifestations]]''' |
| | | | |
| − | *'''[[Hematology]]''' | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| − | *'''[[Heart]]''' | + | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | {{tp|p=32320008|t=ä. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32275288|t=ä. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32232433|t=2020. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Dermatology]]'''
| |
| | | | |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | *'''[[Kidney, urology]]'''
| |
| − | ----
| |
| | | | |
| | + | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| | | | |
| | | | |
| | + | *'''[[Heart]]''' |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | {{tp|p=32370951|t=ä. Missed or Delayed Diagnosis of Kawasaki Disease During the 2019 Novel Coronavirus Disease (COVID-19) Pandemic |pdf=|usr=}}
| |
| | | | |
| − | ----
| + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| | | | |
| | + | *'''[[Dermatology]]''' |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32340627|t=2020. Recommendations from the CSO-HNS taskforce on performance of tracheotomy during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| Zeile 110: |
Zeile 89: |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]''' | + | *'''[[Case reports]]''' |
| − | {{tp|p=32219356|t=ä. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32369030|t=2020. Considerations for Postacute Rehabilitation for Survivors of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Case reports]]'''
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| | + | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − | {{tp|p=32363333|t=ä. A real-time dashboard of clinical trials for COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − |
| |
| − | ----
| |
| − |
| |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32303482|t=ä. Re-emergence of SARS-CoV2 in a discharged COVID-19 case |pdf=|usr=}}
| |
| − | {{tp|p=32299784|t=ä. How do we decide to de-isolate COVID-19 patients?|pdf=|usr=}}
| |
| − | {{tp|p=32105304|t=2020. Positive RT-PCR Test Results in Patients Recovered From COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32276848|t=ä. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32224116|t=ä. Do children need a longer time to shed SARS-CoV-2 in stool than adults?|pdf=|usr=}}
| |
| − | {{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}}
| |
| − | {{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| + | |
| − | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32129805|t=2020. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Running your hospital]]'''
| |
| | | | |
| | | | |
| − | ----
| + | *'''[[Running your hospital]]''' |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| | + | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32325710|t=2020. The COVID-19 Outbreak and Affected Countries Stock Markets Response |pdf=|usr=}}
| |
| − | {{tp|p=32305533|t=ä. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review |pdf=|usr=}}
| |
| − | {{tp|p=32292707|t=ä. Death and contagious infectious diseases: Impact of the COVID-19 virus on stock market returns |pdf=|usr=}}
| |
| − | {{tp|p=32048740|t=2020. Economic impacts of Wuhan 2019?nCoV on China and the world |pdf=|usr=}}
| |
| − | {{tp|p=32311326|t=ä. COVID-19 disrupts vaccine delivery |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 188: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=31967321|t=2020. Cross?species transmission of the newly identified coronavirus 2019?nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32346658|t=ä. SARS-CoV-2 and Bats: From Flight to Fighting COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32277970|t=ä. Strategies to trace back the origin of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Epidemiology]]''' |
| | | | |
| | | | |
| − | *'''[[Epidemiology]]'''
| |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − |
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| | + | *'''[[misc.]]''' |
| | | | |
| | | | |
| − | *'''[[misc.]]''' | + | *'''[[Research tools]]''' |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| − | {{tp|p=C7118609|t=ä. NetNCSP: Nonoverlapping closed sequential pattern mining |pdf=|usr=}} | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | | | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| |
| − | *[biomol.com assays cytokines general spectrum]
| |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| |
| − | *[codexdna.com dna synthesis]
| |
| − | *
| |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
